<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02284126</url>
  </required_header>
  <id_info>
    <org_study_id>AAAN3703</org_study_id>
    <secondary_id>1R01HS022903-01</secondary_id>
    <nct_id>NCT02284126</nct_id>
  </id_info>
  <brief_title>Topical Vancomycin for Neurosurgery Wound Prophylaxis</brief_title>
  <acronym>Vanguard</acronym>
  <official_title>Topical Vancomycin for the Reduction of Surgical Site Infections in Neurosurgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agency for Healthcare Research and Quality (AHRQ)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a collaboration between New York Presbyterian (NYP)-Columbia and NYP-Cornell&#xD;
      that seeks to evaluate the use of topical vancomycin and its reduction on surgical site&#xD;
      infection (SSI) in neurosurgical procedures. Adult patients undergoing neurosurgery at either&#xD;
      institution will be eligible for participation in this randomized control trial. Patients&#xD;
      randomized to the treatment group will receive 2g of vancomycin applied as a powder or paste&#xD;
      to the wound site and/or bone flap. Subjects in the control group will receive the current&#xD;
      standard of care without topical vancomycin. All subjects will undergo swabbing of the&#xD;
      anterior nares and the surgical site prior to surgery, once 10-14 days following the&#xD;
      operation and 90 days following the operation. The primary outcome measure will be surgical&#xD;
      site infection, assessed daily throughout the hospital stay, at the first follow-up visit,&#xD;
      and by telephone at 14-30 days and 90 days (+/- 7 days). Secondary outcomes will include&#xD;
      length of hospital stay, length of intensive care stay, rate of reoperation and patient&#xD;
      mortality. In addition, systemic vancomycin levels will be assessed at 6 hours and 20 hours&#xD;
      postoperatively in each patient. Patients who have an external ventricular drain in place&#xD;
      will have vancomycin levels assessed daily. In patients who have cranial drains placed,&#xD;
      vancomycin concentrations will be analyzed from daily in wound drainage. Skin and nasal flora&#xD;
      will be analyzed to assess the impact of topical vancomycin on the patient microbiome.&#xD;
      Although there has been a decrease in the incidence of infections following craniotomy&#xD;
      secondary to prophylactic intravenous antibiotics, proper sterile techniques, and other&#xD;
      interventions, SSIs continue to significantly impact morbidity, mortality, and cost burden.&#xD;
      Although never studied in neurosurgical procedures other than instrumented spine, the&#xD;
      application of topical vancomycin to the surgical site prior to wound closure has&#xD;
      demonstrated a reduction in SSIs in spine, cardiac and ophthalmologic procedures. The&#xD;
      benefits of using prophylactic vancomycin topically, as opposed to intravenously, include&#xD;
      reduced systemic levels of the drug, and therefore, a decreased probability of adverse events&#xD;
      related to the drug, such as inducing resistance among the native flora. The investigators&#xD;
      propose a single-blinded randomized control trial to evaluate the effectiveness of topical&#xD;
      vancomycin in reducing SSIs rates following neurosurgical procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgical-site infections (SSIs) occur in up to 500,000 patients per year in the United&#xD;
      States. Patients with SSIs require significantly longer hospital stays and higher health care&#xD;
      expenditures. In fact, it is estimated that SSIs are responsible for almost 4 million excess&#xD;
      hospital days and billions of dollars in added hospital charges every year. Additionally,&#xD;
      SSIs are a significant source of morbidity and mortality for surgical patients. Thus, prompt&#xD;
      and definitive measures are necessary in order to redress this significant public health&#xD;
      concern. Over the past few decades, the implementation of a number of preventative&#xD;
      measures-including improved techniques in pre-operative skin antisepsis and antibiotic&#xD;
      prophylaxis-have led to significant reductions in the rate of SSIs. Studies have demonstrated&#xD;
      that approximately half of all SSIs are preventable with the proper use of prophylactic&#xD;
      antibiotics. Despite these dramatic improvements, SSIs remain a tremendous burden on the&#xD;
      healthcare system. Our unpublished analysis of the National Inpatient Sample (NIS) in 2010&#xD;
      identified 117,000 craniotomies with a 2.4% rate of infection and 1.37% rate of&#xD;
      Methicillin-resistant Staphylococcus aureus (MRSA)-associated infection. Extrapolating to the&#xD;
      full national population, there were 585,000 craniotomies and 14,040 post-operative&#xD;
      infections. Published series report the rate of infection in intracranial neurosurgery to&#xD;
      range from 1% to as high as 11%. This rate varies depending on the presence of hardware,&#xD;
      prior radiotherapy, procedure duration, re-operation, and the presence of a CSF leak. The&#xD;
      30-day outcome associated with SSI following craniotomy was recently reported to be a minor&#xD;
      disability in 12.8%, major disability in 7.7% and death in 5.1%. The financial burden of&#xD;
      nosocomial infection in neurosurgery makes up a disproportionate component of the total&#xD;
      national cost burden. A study of nosocomial infection in the US in 1995 estimated a&#xD;
      per-patient cost of $2100 and a total cost of $4.5 billion while a recent British study&#xD;
      focusing on post-craniotomy SSI identified a per-SSI cost of Â£9283, or $14,166. Given the&#xD;
      tremendous potential for lifelong morbidity and mortality as a result of cranial SSIs,&#xD;
      further reductions in the rate of SSI would be essential for the benefit of neurosurgical&#xD;
      patients, as well as for the healthcare system as a whole.Topical formulations of vancomycin&#xD;
      offer the possibility of direct application to the surgical wound, with minimal additional&#xD;
      systemic drug exposure. Adjunctive vancomycin powder applied topically to surgical wound&#xD;
      edges has been shown to significantly lower the SSI rate in both cardiothoracic surgery and&#xD;
      spinal surgery. Importantly, laboratory analyses of blood and wound drainage samples from&#xD;
      patients treated with vancomycin powder have demonstrated high vancomycin concentrations in&#xD;
      the surgical wound, and simultaneously low drug concentrations in the peripheral blood,&#xD;
      thereby confirming minimal systemic absorption in the setting of enhanced protection of the&#xD;
      surgical site. Furthermore, there have been no reports of an increased rate of drug-related&#xD;
      complications with the addition of vancomycin powder to standard antibiotic prophylaxis&#xD;
      regimens.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Actual">November 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Any Surgical-site Infection as Evidenced by Surgeon or Attending Physician Diagnosis, or Signs and Symptoms of Infection Assessed by Phone Call Interview or at In-office Follow-up Consultation</measure>
    <time_frame>30 days &amp; 90 days (+/- 7 days) postoperatively</time_frame>
    <description>Classified as superficial incisional, deep incisional, or organ/space (intradural) infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects That Reported Any Surgical-site Infections</measure>
    <time_frame>30 days &amp; 90 days (+/- 7 days) postoperatively</time_frame>
    <description>As evidenced by surgeon or attending physician diagnosis, or signs and symptoms of infection assessed by phone call interview or at in-office follow-up consultation. Classified as superficial incisional, deep incisional, or organ/space (intradural) infection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Vancomycin Levels</measure>
    <time_frame>6-20 hours post-operatively</time_frame>
    <description>Vancomycin levels in serum will be tested after surgery, any additional fluid collections, but if and only if clinically indicated. The data is collected post-operative and will not be analyzed until the end of the study with another collaborator using Statewide Planning and Research Cooperative System (SPARCS) and New York State (NYS) datasets.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Previously Undetected Vancomycin Resistance</measure>
    <time_frame>90 days postoperatively</time_frame>
    <description>Microbial swabs will be obtained by the clinical coordinator preoperatively, post-operatively, at 10-14 days and at 90 days. Staph aureus isolates from mannitol growth will be tested for vancomycin resistance, comparing preoperative baseline and postoperative timepoints for development of increased vancomycin resistance. The data is collected post-operative and will not be analyzed until the end of the study with another collaborator using SPARCS and NYS datasets.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1103</enrollment>
  <condition>Infection</condition>
  <condition>Surgery</condition>
  <condition>Nervous System Diseases</condition>
  <arm_group>
    <arm_group_label>Topical Vancomycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment group, receive 2 g topical vancomycin hydrochloride (1 g applied as powder, 1 g mixed with sterile solution and applied as paste) at the time of closure, in addition to the standard of care for wound prophylaxis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group, receive standard of care only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Topically applied powder and paste to surgical site at time of closure.</description>
    <arm_group_label>Topical Vancomycin</arm_group_label>
    <other_name>Vancomycin Hydrochloride for Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (18+) neurosurgical procedure (ie.Craniotomy, Craniectomy, and Cranioplasty)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Creatinine &gt; 1.50 mg/dL on admission&#xD;
&#xD;
          -  Vancomycin allergy (documented or self-reported)&#xD;
&#xD;
          -  Evidence of infection at or near the planned surgical site&#xD;
&#xD;
          -  No planned dural or dural-substitute closure&#xD;
&#xD;
          -  Spinal instrumentation (topical vancomycin is already standard of care)&#xD;
&#xD;
          -  No surface area to apply:Carotid endarterectomy, MRI-guided laser ablation&#xD;
&#xD;
          -  Trans-sphenoidal approach&#xD;
&#xD;
          -  Acoustic neuroma resection&#xD;
&#xD;
          -  Surgeon preference for or against use in the given procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E. Sander Connolly, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 3, 2014</study_first_submitted>
  <study_first_submitted_qc>November 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2014</study_first_posted>
  <results_first_submitted>November 30, 2020</results_first_submitted>
  <results_first_submitted_qc>January 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 25, 2021</results_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>E. Sander Connolly</investigator_full_name>
    <investigator_title>Bennett M. Stein Professor of Neurological Surgery Vice Chairman of Neurosurgery Director, Cerebrovascular Research Laboratory Surgical Director, Neuro-Intensive Care Unit</investigator_title>
  </responsible_party>
  <keyword>Vancomycin</keyword>
  <keyword>Anti-Infective Agents, Local</keyword>
  <keyword>Craniotomy</keyword>
  <keyword>Surgical Site Infection</keyword>
  <keyword>Wound Prophylaxis</keyword>
  <keyword>Anti-Bacterial Agents</keyword>
  <keyword>Neurosurgical Procedures</keyword>
  <keyword>Administration, Topical</keyword>
  <keyword>Antibiotic Prophylaxis</keyword>
  <keyword>Antibiotics</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>Neurosurgery</keyword>
  <keyword>Bacterial Infections</keyword>
  <keyword>Central Nervous System Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 23, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT02284126/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Topical Vancomycin</title>
          <description>Treatment group, receive 2 g topical vancomycin hydrochloride (1 g applied as powder, 1 g mixed with sterile solution and applied as paste) at the time of closure, in addition to the standard of care for wound prophylaxis&#xD;
Vancomycin: Topically applied powder and paste to surgical site at time of closure.</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care</title>
          <description>Control group, receive standard of care only</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="552"/>
                <participants group_id="P2" count="551"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="484"/>
                <participants group_id="P2" count="489"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Out of 1103 enrolled subjects, only 973 subjects completed the study and their data have been analyzed and presented here.</population>
      <group_list>
        <group group_id="B1">
          <title>Topical Vancomycin</title>
          <description>Treatment group, receive 2 g topical vancomycin hydrochloride (1 g applied as powder, 1 g mixed with sterile solution and applied as paste) at the time of closure, in addition to the standard of care for wound prophylaxis&#xD;
Vancomycin: Topically applied powder and paste to surgical site at time of closure.</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care</title>
          <description>Control group, receive standard of care only</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="484"/>
            <count group_id="B2" value="489"/>
            <count group_id="B3" value="973"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.1" spread="16.1"/>
                    <measurement group_id="B2" value="53.3" spread="17.0"/>
                    <measurement group_id="B3" value="53.7" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="276"/>
                    <measurement group_id="B2" value="280"/>
                    <measurement group_id="B3" value="556"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="208"/>
                    <measurement group_id="B2" value="209"/>
                    <measurement group_id="B3" value="417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="403"/>
                    <measurement group_id="B2" value="403"/>
                    <measurement group_id="B3" value="806"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="337"/>
                    <measurement group_id="B2" value="339"/>
                    <measurement group_id="B3" value="676"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Any Surgical-site Infection as Evidenced by Surgeon or Attending Physician Diagnosis, or Signs and Symptoms of Infection Assessed by Phone Call Interview or at In-office Follow-up Consultation</title>
        <description>Classified as superficial incisional, deep incisional, or organ/space (intradural) infection</description>
        <time_frame>30 days &amp; 90 days (+/- 7 days) postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topical Vancomycin</title>
            <description>Treatment group, receive 2 g topical vancomycin hydrochloride (1 g applied as powder, 1 g mixed with sterile solution and applied as paste) at the time of closure, in addition to the standard of care for wound prophylaxis&#xD;
Vancomycin: Topically applied powder and paste to surgical site at time of closure.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Control group, receive standard of care only</description>
          </group>
        </group_list>
        <measure>
          <title>Any Surgical-site Infection as Evidenced by Surgeon or Attending Physician Diagnosis, or Signs and Symptoms of Infection Assessed by Phone Call Interview or at In-office Follow-up Consultation</title>
          <description>Classified as superficial incisional, deep incisional, or organ/space (intradural) infection</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="484"/>
                <count group_id="O2" value="489"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subject visited doctor and received antibiotics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject reports any possible symptom of surgical site infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="344"/>
                    <measurement group_id="O2" value="355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive skin culture or hospital readmission for surgical site infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects That Reported Any Surgical-site Infections</title>
        <description>As evidenced by surgeon or attending physician diagnosis, or signs and symptoms of infection assessed by phone call interview or at in-office follow-up consultation. Classified as superficial incisional, deep incisional, or organ/space (intradural) infection.</description>
        <time_frame>30 days &amp; 90 days (+/- 7 days) postoperatively</time_frame>
        <population>Out of 1103 enrolled subjects, only 973 subjects completed the study and their data have been analyzed and presented here.</population>
        <group_list>
          <group group_id="O1">
            <title>Topical Vancomycin</title>
            <description>Treatment group, receive 2 g topical vancomycin hydrochloride (1 g applied as powder, 1 g mixed with sterile solution and applied as paste) at the time of closure, in addition to the standard of care for wound prophylaxis&#xD;
Vancomycin: Topically applied powder and paste to surgical site at time of closure.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Control group, receive standard of care only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects That Reported Any Surgical-site Infections</title>
          <description>As evidenced by surgeon or attending physician diagnosis, or signs and symptoms of infection assessed by phone call interview or at in-office follow-up consultation. Classified as superficial incisional, deep incisional, or organ/space (intradural) infection.</description>
          <population>Out of 1103 enrolled subjects, only 973 subjects completed the study and their data have been analyzed and presented here.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="484"/>
                <count group_id="O2" value="489"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="344"/>
                    <measurement group_id="O2" value="355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Vancomycin Levels</title>
        <description>Vancomycin levels in serum will be tested after surgery, any additional fluid collections, but if and only if clinically indicated. The data is collected post-operative and will not be analyzed until the end of the study with another collaborator using Statewide Planning and Research Cooperative System (SPARCS) and New York State (NYS) datasets.</description>
        <time_frame>6-20 hours post-operatively</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of Previously Undetected Vancomycin Resistance</title>
        <description>Microbial swabs will be obtained by the clinical coordinator preoperatively, post-operatively, at 10-14 days and at 90 days. Staph aureus isolates from mannitol growth will be tested for vancomycin resistance, comparing preoperative baseline and postoperative timepoints for development of increased vancomycin resistance. The data is collected post-operative and will not be analyzed until the end of the study with another collaborator using SPARCS and NYS datasets.</description>
        <time_frame>90 days postoperatively</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Topical Vancomycin</title>
          <description>Treatment group, receive 2 g topical vancomycin hydrochloride (1 g applied as powder, 1 g mixed with sterile solution and applied as paste) at the time of closure, in addition to the standard of care for wound prophylaxis&#xD;
Vancomycin: Topically applied powder and paste to surgical site at time of closure.</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care</title>
          <description>Control group, receive standard of care only</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="552"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="552"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Left Ventricular Thrombus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing loss</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="552"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatic Necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Changes</sub_title>
                <description>E. Coli</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="552"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Unplanned Medical Visit</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="552"/>
                <counts group_id="E2" events="37" subjects_affected="37" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Bleeding at drain site</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Gait instability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Epidural Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy Symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Surgical Site Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="552"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infeciton</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vision Impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Facial Sensory Loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Dysarthria/Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Cognitive Impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="552"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Stroke/Cerebrovasular accident</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="552"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Drop foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Pneumocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="552"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="552"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing Change</sub_title>
                <counts group_id="E1" events="26" subjects_affected="24" subjects_at_risk="552"/>
                <counts group_id="E2" events="27" subjects_affected="26" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Unplanned Medical Visit</sub_title>
                <counts group_id="E1" events="38" subjects_affected="35" subjects_at_risk="552"/>
                <counts group_id="E2" events="30" subjects_affected="26" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy Symptoms</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="552"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal changes</sub_title>
                <description>Diarrhea, nausea, constipation, vomiting, etc</description>
                <counts group_id="E1" events="33" subjects_affected="30" subjects_at_risk="552"/>
                <counts group_id="E2" events="36" subjects_affected="34" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. E. Sander Connolly Jr.</name_or_title>
      <organization>Columbia University Irving Medical Center</organization>
      <phone>2123054118</phone>
      <email>esc5@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

